Back

Insights from the vicadrostat phase 2 study and implications for further clinical development

19 May 2025 (12:53 - 13:03)
Organised by: Logo
Congress Presentation Part of: Does aldosterone synthase inhibition hold a key to transforming cardiorenal care? Aldosterone Antagonists HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail
Welcome and introductions
Slides
Presentation thumbnail
The integrated nature of cardiorenal metabolic health
Professor L. Lund (Stockholm, SE)
Slides
Presentation thumbnail
The role of aldosterone and its part in cardiorenal disease
Doctor M. Costanzo (Naperville, US)
Slides
Presentation thumbnail
Aldosterone synthase inhibition and the future CRM treatment landscape
Professor J. Butler (Dallas, US)
Slides
Presentation thumbnail
Outlook, panel discussion and Q&A
Slides

Access the full session

Session thumbnail
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
Video

The Event

Event poster

Heart Failure 2025

19 May 2025 12:53 CET
You may be interested in
thumbnail
Congress Presentation
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
28 August 2020
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Tyrosine kinase inhibitors
30 August 2025
thumbnail
Congress Session
Innovative drug therapies in heart failure
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources